Ricciuti et al. [53] demonstrated that KEAP1 and STK11 mutations generate an immune-exclusionary tumor microenvironment, limiting PD-(L)1 response in NSCLC; therefore, combining metabolic or redox modulation with immune checkpoint blockade could restore sensitivity. The gene discussed is STK11; the disease is non-small cell lung carcinoma.